Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study

Wang, Man; Tong, Jianhua; Zhu, Gang; Liang, Guang-ming; Yan, Hongfei; Wang, Xiuzhen

doi:10.1016/j.schres.2012.02.021

Cited by 72 publications

(56 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Children are unlikely to be a niche market for a novel obesity drug, but metformin has also been studied in patients with mood disorders [39] and schizophrenia [40]. These patients include schizophrenic patients newly treated with anti-psychotic drugs, notably olanzapine, that promote weight gain [41,42]. The body weight benefits achieved in some of these studies have been markedly greater than in type 2 diabetic patients.…”

Section: Metformin and Anti-psychotic Drug-induced Weight Gainmentioning

confidence: 99%

Horizons in the Pharmacotherapy of Obesity

Arch

2015

Curr Obes Rep

View full text Add to dashboard Cite

Abstract:Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT2C agonist lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators' caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. Others remain optimistic about more conventional routes to pharmacotherapy.3

show abstract

Section: Metformin and Anti-psychotic Drug-induced Weight Gainmentioning

confidence: 99%

Horizons in the Pharmacotherapy of Obesity

Arch

2015

Curr Obes Rep

View full text Add to dashboard Cite

show abstract

“…There have been at least two recent double-blind, placebo-controlled RCTs 29,30 in Chinese adult populations which were not included in the previous systematic reviews. A brief summary of these two new studies is shown in Table 5.…”

Section: New Evidencementioning

confidence: 99%

“…A brief summary of these two new studies is shown in Table 5. 29,30 Mechanism of action Metformin is an antidiabetic agent that has been suggested to act: (1) by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis; (2) in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation; and (3) by delaying intestinal glucose absorption. 31 Effects on body weight with metformin appear to be due to reduction in appetite rather than increases in calorie expenditure.…”

Section: New Evidencementioning

confidence: 99%

Role of metformin in the management of antipsychotic-induced weight gain

Prajapati¹

2014

Prog. Neurol. Psychiatry

View full text Add to dashboard Cite

O besity is a growing public health concern with significant economic burden. In general, someone with a BMI of 25kg/m 2 or over is classed as overweight and with a BMI of 30kg/m 2 or over as obese. A waist circumference of 94cm or over in men and 80cm or over in women carries a high risk for coronary heart disease and the metabolic syndrome. The prevalence of both diabetes and obesity among individuals with schizophrenia and affective disorders is 1.5-2.0 times higher than in the general population. People with mental illness are three times more likely to develop diabetes and twice as likely to die from heart disease. 1 Many characteristics of people with schizophrenia, such as sedentary behaviour, may contribute to the apparently higher prevalence of metabolic abnormalities.With an increasing trend for using atypical antipsychotics (second-generation antipsychotics) over typical antipsychotics (first-generation antipsychotics) for various psychiatric disorders, the adverse effect concern has shifted from extrapyramidal side effects to weight gain and impaired metabolic control. 2 In addition to adversely affecting quality of life and medication adherence, weight gain and metabolic abnormalities are reliable risk factors for premature cardiovascular morbidity and mortality, and diabetes.

show abstract

“…The authors concluded that metformin is effective in promoting weight loss and improving insulin resistance induced by antipsychotics in patients with the first episode of schizophrenia. 4 In a double-blinded, placebo-controlled trial, 40 adult inpatients (age range, 18 to 50 years) with firstepisode schizophrenia were randomized to receive olanzapine (15 mg/day) with either metformin or placebo for 12 weeks. Metformin dosing was administered as 250 mg 3 times daily.…”

Section: Controlled Trialsmentioning

confidence: 99%

“…4,7 The most frequently cited reactions related to study withdrawal were nausea or psychosis exacerbation. 4,7 (Continued on page 777) …”

Section: Safetymentioning

confidence: 99%

Metformin: Prevention and Treatment of Antipsychotic-Induced Weight Gain

Generali

Cada²

2013

Hosp Pharm

View full text Add to dashboard Cite

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

show abstract

Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study

Cited by 72 publications

References 19 publications

Horizons in the Pharmacotherapy of Obesity

Horizons in the Pharmacotherapy of Obesity

Role of metformin in the management of antipsychotic-induced weight gain

Metformin: Prevention and Treatment of Antipsychotic-Induced Weight Gain

Contact Info

Product

Resources

About